CD38

Overview

CD38 explanation

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Tags

The following is a listing of myeloma tags that are associated with this tag.

Bispecific Antibody

A bispecific antibody is a drug that has been designed to simultaneously target two different proteins. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells.

Bispecific T Cell Engager (BiTE)

BiTEs are a type of immunotherapy. They consist of monoclonal antibodies that can target and bind to both myeloma cells and T Cells.

CAR T Cell

CAR T Cell therapy is a new way to treat multiple myeloma using your own immune system to target and destroy cancer cells.

Monoclonal Antibody

Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.

Resources

There are no resources, links or videos to display for this tag.